Diseases / Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
DiseaseIdiopathic pulmonary fibrosis is a chronic progressive fibrosing interstitial lung disease of unknown cause characterized by worsening dyspnea, cough, and declining lung function. It primarily affects older adults and has a poor prognosis despite available antifibrotic therapies. Diagnosis typically requires multidisciplinary evaluation and exclusion of secondary causes.
- Trials
- 565
- Recruiting
- 73
- Completed
- 306
- With results
- 121
Last revised
Pipeline
Phase by status
| Phase | Recruiting | Not yet | By invitation | Active | Completed | Terminated | Withdrawn | Suspended | Unknown | Approved for marketing | No longer available | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Early Phase 1 | 2 | 1 | — | — | 3 | — | — | — | 3 | — | — | 9 |
| Phase 1 | 5 | 4 | — | 2 | 68 | 7 | — | 1 | 4 | — | — | 91 |
| Phase 1/2 | 1 | — | — | 1 | 9 | — | 1 | — | 1 | — | — | 13 |
| Phase 2 | 20 | 6 | — | 10 | 65 | 17 | 8 | — | 6 | — | — | 132 |
| Phase 2/3 | 1 | — | — | — | 2 | 1 | — | — | — | — | — | 4 |
| Phase 3 | 8 | 3 | 1 | 1 | 24 | 14 | — | — | 2 | — | — | 53 |
| Phase 4 | — | — | — | — | 6 | 2 | 2 | — | 2 | — | — | 12 |
| Not applicable | 9 | 5 | — | 2 | 42 | 5 | — | — | 15 | — | — | 78 |
| Unknown | 27 | 9 | 3 | 11 | 87 | 3 | 5 | — | 25 | 2 | 1 | 173 |
Trials started per year
Conditions studied, by phase
| Condition | Early Phase 1 | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | Phase 4 | Not applicable | Unknown | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Idiopathic Pulmonary Fibrosis | 9 | 91 | 13 | 132 | 4 | 53 | 12 | 78 | 173 | 565 |
| Lung Diseases, Interstitial | 1 | 3 | 1 | 16 | 2 | 8 | 2 | 19 | 50 | 102 |
| Pulmonary Fibrosis | 1 | 10 | 1 | 31 | 3 | 13 | — | 8 | 21 | 88 |
| Lung Diseases | — | 4 | — | 7 | 2 | 4 | — | 3 | 5 | 25 |
| Pulmonary Disease, Chronic Obstructive | 1 | 2 | 1 | — | — | — | 1 | 7 | 13 | 25 |
| Fibrosis | — | 5 | — | 12 | — | 5 | — | 1 | 1 | 24 |
| Idiopathic Interstitial Pneumonias | — | 2 | 1 | 6 | — | 2 | — | — | 9 | 20 |
| Cough | — | 1 | — | 6 | — | 2 | — | 3 | 1 | 13 |
| Hypertension, Pulmonary | — | 2 | — | 5 | — | 2 | 2 | — | 2 | 13 |
| Sarcoidosis | — | — | — | 1 | — | — | — | 2 | 10 | 13 |
Most active sponsors
| # | Sponsor | Trials | Phase 3 |
|---|---|---|---|
| 1 | Boehringer Ingelheim | 35 | 5 |
| 2 | Hoffmann-La Roche | 16 | 3 |
| 3 | Royal Brompton & Harefield NHS Foundation Trust | 11 | 1 |
| 4 | Bristol-Myers Squibb | 9 | 2 |
| 5 | Duke University | 7 | 3 |
| 6 | Genentech, Inc. | 7 | 4 |
| 7 | GlaxoSmithKline | 7 | 0 |
| 8 | Sunshine Lake Pharma Co., Ltd. | 7 | 1 |
| 9 | Actelion | 6 | 3 |
| 10 | Assistance Publique - Hôpitaux de Paris | 6 | 1 |
Most studied interventions
| # | Intervention | Trials |
|---|---|---|
| 1 | pirfenidone | 41 |
| 2 | nintedanib | 36 |
| 3 | Sildenafil Citrate | 8 |
| 4 | Blood Specimen Collection | 6 |
| 5 | BI 1015550 | 5 |
| 6 | Bosentan | 5 |
| 7 | pamrevlumab | 5 |
| 8 | treprostinil | 5 |
| 9 | Acetylcysteine | 4 |
| 10 | Exercise | 4 |
Evidence
- Results reported
- 39.5%121 of 306 completed
- Published
- 8.2%25 of 306 completed
- Primary endpoint met
- 39.8%33 of 83 analyses
- Median months to report
- 13
Documents disclosed
Trial profile
- Median enrollment
- 68
- Median duration
- 29.1months
- Countries
- 63
- Study sites
- 5890
Who is enrolled
Median enrollment by phase
- Early Phase 1
- 20
- Phase 1
- 26
- Phase 1/2
- 23
- Phase 2
- 74
- Phase 2/3
- 139
- Phase 3
- 325
- Phase 4
- 54
- Not applicable
- 40
- Unknown
- 150
Where trials run
Busiest cities
| # | City | Country | Trials |
|---|---|---|---|
| 1 | London | United Kingdom | 68 |
| 2 | Philadelphia | United States | 64 |
| 3 | Birmingham | United States | 63 |
| 4 | Nashville | United States | 60 |
| 5 | Los Angeles | United States | 56 |
| 6 | New York | United States | 54 |
| 7 | Charleston | United States | 50 |
| 8 | Boston | United States | 48 |
| 9 | Salt Lake City | United States | 48 |
| 10 | Ann Arbor | United States | 47 |
Terminations
- Terminated
- 49
- Withdrawn
- 16
- Suspended
- 1
- Stopped for recruitment
- 1.8%10 of 565 trials
Stated reasons
Reasons are grouped from the sponsor's own wording with a rule-based classifier; the original text is shown below.
Recently stopped
| Trial | Status | Stated reason | Stopped |
|---|---|---|---|
| NCT05785624 Terminated | Terminated | Sponsor decided to discontinue the study after review of clinical data by the iDMC. This decision was based on unblinded evaluation of clinical efficacy which showed a trend towards futility \& was not related to any safety concerns of vixarelimab. | 2026-01-12 |
| NCT04643769 Suspended | Suspended | Partnership activities ongoing | 2025-12-30 |
| NCT06317285 Terminated | Terminated | The study met futility criteria at pre-planned interim analysis, showing no clinical efficacy of the investigational drug. Based on the lack of efficacy at the interim data review, the sponsor decided to terminate the study. | 2025-10-01 |
| NCT06360094 Terminated | Terminated | Sponsor decision | 2025-09-02 |
| NCT05349760 Withdrawn | Withdrawn | to focus resources on other studies | 2025-06-30 |
| NCT06097260 Terminated | Terminated | DSMB recommendation | 2025-04-04 |
| NCT05359965 Terminated | Terminated | Lack of enrollment | 2025-02-11 |
| NCT05032066 Terminated | Terminated | The trial was terminated due to not meeting primary or key secondary endpoints. | 2025-01-02 |
| NCT04263727 Terminated | Terminated | Sponsor decision to terminate study | 2024-11-21 |
| NCT05497284 Terminated | Terminated | Sponsor Decision | 2024-09-26 |
Trial records
Individual study records live on ClinicalTrials.gov. A sample of the trials counted above:
Search all Idiopathic Pulmonary Fibrosis trials on ClinicalTrials.gov →